New Open-Source Tool Hunts Ultra-Rare Cancer DNA Fingerprints in Blood

Detecting the faintest molecular traces of cancer hiding in a patient’s bloodstream has long been one of the most demanding challenges in modern oncology. Circulating tumor DNA, the genetic debris shed by malignant cells into the blood, exists alongside an ocean of healthy cell-free DNA, and the sequencing machines used to read these fragments make errors at rates that easily swamp true signals. A team of researchers at the University of Groningen and University Medical Center Groningen has now unveiled a computational solution that turns this problem on its head. Their open-source software, called MNVista, exploits a quirk of lymphoma biology to identify multi-nucleotide variants, clusters of mutations that occur together so rarely by chance that their presence in blood plasma becomes an unmistakable signature of residual disease. The work, published in BMC Bioinformatics, demonstrates detection of tumor DNA at dilutions far below the thresholds that standard variant callers can reach.

The clinical motivation behind the tool centers on minimal residual disease, the microscopic burden of cancer cells that persists after treatment and drives relapse. In germinal center B-cell derived lymphomas, a family of blood cancers that includes some of the most common lymphoma subtypes, the malignant cells carry a distinctive legacy of their origin. During their development in germinal centers, these cells activate a molecular machinery known as somatic hypermutation, which deliberately scrambles DNA in antibody genes to generate immune diversity. The machinery is not perfectly targeted, however, and it also leaves clusters of simultaneous mutations scattered across the genome, particularly within super-enhancer regions, stretches of DNA that control the activity of key genes in B cells. These clustered mutations, called multi-nucleotide variants, or MNVs, act as patient-specific fingerprints that are extraordinarily unlikely to arise from sequencing noise.

MNVista works by searching for co-occurring single-nucleotide variants and evaluating candidate pairs with a Bayesian statistical model that incorporates read-level metrics from the sequencing data. Rather than requiring specialized file formats, the tool accepts standard VCF and indexed BAM files, the common currencies of next-generation sequencing pipelines, which means laboratories can slot it into existing workflows with minimal friction. The software can operate with or without matched normal control samples, a flexibility that matters in clinical settings where a healthy tissue reference is not always available. By scoring how likely it is that two or more nearby mutations appeared together on the same set of sequencing reads by genuine biology rather than by independent errors, the Bayesian framework filters out noise while preserving true clustered variants.

The performance gains reported by the team are striking. In publicly available dilution series, in which DNA from lymphoma patients was diluted into healthy background DNA to simulate minimal residual disease, MNVista detected patient-specific multi-nucleotide variants down to a variant allele fraction of 0.0025 percent, equivalent to 25 parts per million. The widely used standard caller Mutect2, by comparison, reached a detection limit of 1,783 parts per million on the same data. That gap spans nearly two orders of magnitude, and it translates directly into clinical potential: the lower the fraction of tumor DNA that can be reliably detected, the earlier a relapse can be flagged and the more confidently a patient can be declared disease-free after therapy.

The mathematics behind this sensitivity advantage are worth unpacking. Sequencing errors strike individual bases essentially at random, so the probability that two specific errors occur side by side on the same DNA fragment is the product of two independent error rates, an astronomically small number. When somatic hypermutation produces genuinely linked mutations, however, those bases are altered together in the tumor genome and therefore appear together in every descendant DNA fragment circulating in the blood. By demanding co-occurrence rather than trusting any single variant call, MNVista effectively multiplies its power to distinguish signal from noise. The researchers showed that the tool recovered complex multi-nucleotide variants composed of up to nine co-occurring single-nucleotide changes, a combinatorial specificity so extreme that it implies a theoretical detection limit below the 1 part per million threshold that the National Comprehensive Cancer Network has cited as a target for clinical minimal residual disease detection.

Validation did not rest on patient dilution data alone. The team also ran synthetic benchmark experiments in which they spiked artificial multi-nucleotide variants into real sequencing data and compared the results against Mutect2. On clean backgrounds, MNVista delivered near-perfect performance, recovering the spiked-in variants with essentially no false positives. More revealing, however, was the stress test: when the researchers synthetically introduced background single-nucleotide variants into genuine patient data, including both real somatic variants and sequencing artifacts, MNVista’s accuracy remained robust while Mutect2’s performance degraded. This resilience to noisy backgrounds is critical, because real clinical samples are never as pristine as benchmark datasets, and a caller that collapses under background variation offers little value at the bedside.

The design choices embedded in MNVista reflect a deliberate effort to bridge the gap between research algorithms and clinical practice. Many specialized ultra-sensitive detection methods demand bespoke wet-lab protocols, custom capture panels, or proprietary analysis chains, all of which slow adoption and add cost. MNVista instead operates entirely downstream of standard sequencing, consuming ordinary VCF and BAM files that any clinical genomics facility already produces. This architecture means the tool does not require new laboratory infrastructure or revalidation of sequencing chemistry; it simply extracts more information from data that already exist. For hospitals running lymphoma surveillance programs, the path from sample to result could therefore remain largely unchanged apart from an additional analysis step.

The implications for B-cell lymphoma care could be substantial. Minimal residual disease monitoring using cell-free DNA is increasingly recognized as a way to personalize treatment intensity, identifying patients who need additional therapy before overt relapse and sparing others from unnecessary toxicity. In lymphomas driven by germinal center programs, the abundance of super-enhancer-associated multi-nucleotide variants provides a rich reservoir of markers that are unique to each patient’s tumor, sidestepping the need to hunt for recurrent mutations that may not exist in every case. Because these clustered signatures arise from the tumor’s own mutational machinery, they can be catalogued at diagnosis from tumor tissue and then tracked in blood over time, giving oncologists a quantitative, dynamic measure of disease burden measured in parts per million.

Limitations and open questions remain, as with any new method. The tool’s sensitivity figures derive from publicly available dilution series and synthetic benchmarks, and prospective clinical studies will be needed to confirm that ultra-sensitive MNV detection translates into earlier relapse detection and improved outcomes in real patient cohorts. The approach is also specifically tailored to cancers shaped by somatic hypermutation and related error-prone processes, so its applicability to solid tumors with different mutational signatures remains to be established. Nevertheless, the software is released as open source, which invites the broader bioinformatics community to test, adapt, and extend it, and the authors acknowledge support from the Anita Veldman Foundation and the high-performance computing resources of the University of Groningen in bringing the project to fruition.

What makes this study resonate beyond lymphoma is its demonstration that biological insight can outperform brute-force engineering in the quest for analytical sensitivity. Rather than pushing sequencing depth ever higher, the Groningen team harnessed a distinctive mutational process to create signatures whose statistical improbability alone defeats sequencing noise. If the tool’s performance holds in clinical validation, patients with germinal center B-cell lymphomas may one day benefit from relapse surveillance capable of spotting one cancer-derived DNA fragment among a hundred thousand healthy ones, a detection limit that until recently belonged to the realm of theory rather than routine laboratory practice.

Subject of Research: Computational detection of multi-nucleotide variants in cell-free DNA for minimal residual disease monitoring in B-cell lymphoma

Article Title: MNVista: accurate identification of multi-nucleotide variants from next generation sequencing data

Article References: MNVista: accurate identification of multi-nucleotide variants from next generation sequencing data. (n.d.). https://doi.org/10.1186/s12859-026-06702-x

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06702-x

Keywords: MNVista, multi-nucleotide variants, cell-free DNA, minimal residual disease, B-cell lymphoma, circulating tumor DNA, next-generation sequencing, somatic hypermutation, super-enhancer regions, Bayesian model, variant calling, bioinformatics